Lexicon Pharmaceuticals Q1 net loss narrows

Lexicon Pharmaceuticals

07/05/2026 12:41

Overview

US biopharma firm's Q1 total revenue surged on milestone payments, while product revenue declined yr/yr

Net loss narrowed sharply from prior year, reflecting lower R&D and SG&A expenses

Company bolstered cash position with capital raise and $100 mln loan facility

Result Drivers

MILESTONE PAYMENTS - Q1 revenue was mainly driven by $20 mln in milestone payments from Novo Nordisk for LX9851 development

LOWER EXPENSES - R&D and SG&A expenses declined due to completion of a clinical trial and reduced marketing and personnel costs

Company press release: ID:nGNX43CQst

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.01
Q1 Net Income
-$1.04 mln
Q1 Operating Expenses
$22.10 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for Lexicon Pharmaceuticals Inc is $2.30, about 43.7% above its May 6 closing price of $1.60

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)